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ABSTRACT 
Exploring Methodologies to Prepare Selenium Modified Oligonucleotides 
Christopher Liczner  
 
X-ray crystallography has been central in determining structure-function 
relationships for biomacromolecules, such as nucleic acids and proteins, leading to a 
greater understanding of biochemical processes. The major barriers to nucleic acid 
structure determination by X-ray crystallography are the processes of crystallization and 
phasing. One strategy to overcome the latter challenge involves replacement of oxygen 
with selenium in a nucleotide. In the past two decades, selenium has been incorporated 
into oligonucleotides at many different sites, each with their specific advantages and 
limitations. Preparation of selenium modified nucleic acids often requires the multi-step 
synthesis of specialized phosphoramidites incorporated into oligonucleotides by solid-
phase synthesis.  It would be desirable to simplify the synthetic process to prepare these 
selenium containing oligonucleotides, which may result in their greater accessibility for 
crystallographers engaged in the determination of high resolution structural studies of 
nucleic acid structures. 
In one approach, a simplified, greener and more versatile methodology to 
incorporate selenium into a solid support-bound oligonucleotide at the O-4 position of 
thymidine was explored. A range of reaction and deprotection conditions were 
evaluated, with promise of this approach demonstrated when selenium incorporation 
was attempted at a 5’-end residue of an oligonucleotide, followed by deprotection using 
a sterically hindered base. Another approach investigated the preparation of an 
oligonucleotide with 2’-deoxy-6-selenoinosine, a derivative of interest which was inspired 
  ii 
by the base pairing properties of 2’-deoxyinsoine towards other nucleobases. In the 
isolation and purification of this oligonucleotide, it was observed that the major product 
obtained was a non-complementary homodimer oligonucleotide connected by an 
interstrand diselenide bridge. Conditions to remove this cross-link were evaluated and 
expand the potential of selenium modified nucleic acids beyond X-ray crystallography for 
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Chapter 1. General Introduction 
 
1.1. The Structure and Properties of Nucleic Acids 
 
2’-Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are polymeric 
biological molecules common in all living organisms. These molecules are 
composed of nucleotide monomers, each consisting of three components; a 
nitrogenous heterocyclic base, a pentose sugar and a phosphate group. The 
pentose sugar is 2’-deoxyribose in DNA and ribose in RNA, with a differentiating 
hydroxyl group at the 2’-position, as shown in Figure 1.1. The pentose sugar 
adopts different conformations (also referred to as sugar puckers) in order to 
alleviate eclipsing interactions between their substituents. Two common twisted 
conformation sugar puckers are C2’-endo (Southern - S) and C3’-endo (Northern 
-N), shown in Figure 1.1.  The heterocyclic bases are derivatives of purines and 
Figure 1.1: Nucleoside structures with common sugar puckers, indicating the numbering 
system of the sugar, purine and pyrimidine bases. 
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pyrimidines. In DNA, the purine heterocyclic bases are adenine and guanine and 
the pyrimidine heterocyclic bases are cytosine and thymine. These bases are 
common to RNA, but with uracil replacing thymine. Other heterocyclic bases 
exist, such as hypoxanthine (commonly found in tRNA, used during the 
translation process) and 5-methyl-cytosine (used for regulating gene 
transcription), amongst others. The structures of these heterocycles are shown in 
Figure 1.1, depicted as nucleosides (i.e. without phosphate groups). The 
heterocyclic bases are connected to the C-1’ position of the pentose sugar by a 
β-glycosidic bond so that the heterocycle and 5’ carbon are on the same side of 
the pentose sugar. The heterocyclic bases can exist in any conformation, but 
they are normally found in the syn- or anti-conformations depending on steric 
influences. The syn-conformation has the C-4 (purines) or C-2 (pyrimidines) 
atoms of the heterocyclic base oriented cis with respect to the O-4’ of the 
pentose sugar, whereas the anti-conformation has the C-4 or C-2 atoms of the 
heterocyclic base oriented trans with respect to the O-4’ of the pentose sugar.1 
The primary structure of nucleic acids consists of nucleoside monomers 
connected through 3’-5’ phosphodiester linkages. Natural nucleic acid sequences 
consist of a phosphate group at the 5’-end which is not involved in a 
phosphodiester linkage and a hydroxyl group at the 3’-end. Under physiological 
conditions, the phosphodiester backbone is negatively charged, allowing for 
optimal solubility in aqueous media. The primary sequence gains its uniqueness 
from the heterocyclic bases present. To designate such a sequence, single letter 
codes are used for each nucleotide monomer, namely A, G, C, T, U and I for 
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adenosine, guanosine, cytidine, thymidine, uridine and inosine, respectively. To 
differentiate DNA from RNA in strand naming, a “d” is used for deoxyribose and 
an “r” is used for ribose.1 
Nucleic acids are polymorphic, capable of forming many different 
secondary structures. Recognition between the strands of nucleic acids is 
primarily attributed to hydrogen bonding between the heterocyclic bases. The 
hydrogen bonding pattern of the heterocycle’s dominant tautomeric form lead to 
cytosine base pairing with guanine and adenine base pairing with thymine/uracil. 
These interactions are known as Watson-Crick base pairing, which is the 
classical interaction between antiparallel DNA strands forming the double helix. 
The Hoogsteen face of the heterocyclic bases is also capable of hydrogen 
bonding, with an example depicted in Figure 1.3A. Inosine, a universal base, is 
capable of hydrogen bonding with 
any of the canonical bases.2 
Strand interaction is not solely 
dependent on hydrogen bonding; 
sequence identity and environmental 
conditions also play a key role. DNA 
can adopt different anti-parallel 
double helical forms, the most 
common being the A-form and B-
form,3 as shown in Figure 1.2.4 At 
low humidity and high salt 
Figure 1.2: Molecular models of A-form and B-
form DNA (taken with permission from 
reference 4). 
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concentration the A-form dominates. This double helix is right-handed, the 
sugars are C3’-endo and adjacent phosphates are separated by 6 Å.1 At high 
humidity and low salt concentrations the B-form dominates which is the most 
common form of DNA found in nature. This double helix is right-handed, the 
sugars are C2’-endo and adjacent phosphates are separated by 6.77 Å.1 The 
relatively closer negatively charged phosphate groups in A-form DNA are 
tolerated due to the high salt concentration, which masks the electrostatic 
repulsions. Although RNA is more commonly known to exist in its single-stranded 
form (mRNA) or in various structures such as hairpin loops in tRNA or rRNA, it 
can also form a Watson-Crick anti-parallel double helix.5 This duplex is right-
handed and the sugars adopt a C3’-endo sugar pucker, with an overall structure 
resembling that of A-form DNA.1 Nucleic acids can also adopt more complex 
secondary structures than the double helix. Generally, the requirements for the 
formation of such structures depend on nucleobase composition and/or 
environmental factors. For example, the G-quadruplex6,7 forms with G-rich 
sequences at neutral pH and requires specific metal cations, such as Na+ and K+, 
to be present for stabilization. In this, four guanines associate so that each base 
is engaged in four hydrogen bonds through Hoogsteen and Watson-Crick base 
pairing to form a nearly planar structure known as the G-quartet, shown in Figure 
1.3A.8 When two or more quartets are stacked, they form a G-quadruplex, shown 
in Figure 1.3B.8 Each guanine directs its O-6 carbonyl oxygen towards the 
center of the quartet which interacts with a positively charged cation at the 
center. This secondary structure can form by both intramolecular and 
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intermolecular means, in a parallel 
or anti-parallel fashion. X-ray 
crystallography (described in 
Chapter 1.3) and NMR have been 
paramount in determining the 
nucleic acid structures discussed 
herein.  
Specific properties of nucleic acids can be utilized in order to study these 
molecules. Firstly, the heterocyclic bases absorb strongly, with a molar extinction 
coefficient of 104 M-1 cm-1 at 260 nm. The (deoxy)ribose-phosphate backbone is 
essentially transparent to light in the ultraviolet region. The relatively strong 
absorption at this characteristic wavelength can be used to quantify the amount 
Figure 1.3: (A) The interactions of a G-quartet illustrating the Watson-Crick and Hoogsteen 
faces of guanine. (B) Schematic diagrams of an intramolecular (left) and intermolecular 










face of G4 
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of nucleic acid present in solution using the Beer-Lambert law. Another crucial 
property is the difference in absorbance between nucleic acids strands which are 
base-paired and dissociated. In secondary structures, the bases are stacked with 
one another, causing a decrease in the molar extinction coefficient due to dipole-
dipole interactions between the bases. When the strands dissociate due to 
environmental changes, such as an increase in temperature, the base stacking 
interactions are reduced which results in an increase in the molar extinction 
coefficient and therefore an increase in absorbance. This phenomenon is known 
as hyperchromicity and is the general basis for UV thermal denaturation 
experiments where absorbance at a specific wavelength is monitored as the 
temperature is increased. A sigmoidal transition denotes a two-state cooperative 
process: one population of nucleic acid secondary structures dissociates to 
another population. A common example of this phenomenon is DNA duplex 
dissociation into its single strands. The melting temperature (Tm) of such a 
transition is the temperature at which the ratio of the different populations in 
solution is 1:1. This occurs at the temperature where there is the greatest change 
in absorbance (inflection point), determined by taking the first derivative of the 
curve. This parameter can be used to assess the relative stability of secondary 
structures, however, for a reliable comparison, the experimental conditions must 
be identical since the Tm is sensitive to many factors, such as the buffer used and 
pH. Finally, nucleic acids are chiral molecules. The heterocyclic bases of nucleic 
acids are not chiral, however, the attachment between the N-9 of purines or N-1 
of pyrimidines to the C-1’ atom of the sugar by the glycosylic bond results in a 
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chiral disruption to their absorption of UV light. Nucleic acids are therefore able to 
be studied by circular dichroism (CD) spectroscopy. A CD signal is produced 
from the differential absorption of left and right circularly polarized light. The 
many secondary structures of nucleic acids (B-form, A-form, G-quadruplex DNA, 
etc.) exhibit characteristic CD profiles, allowing for rapid qualitative determination 
of structural information.1 
 
1.2. Solid-Phase Synthesis of Oligonucleotides  
One of the most widely used approaches for the assembly of 
oligonucleotides (sequences of less than 100 nucleotides) is solid-phase 
Scheme 1.1: The oligonucleotide solid-phase synthesis cycle. 
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synthesis using phosphoramidite chemistry.9,10,11 Solid-phase synthesis is 
especially useful in that it can be adapted to automated systems, impurities and 
excess reagents can be washed away without the need for purification and large 
excess of reagents can be used to drive reactions to completion in short time 
periods.12 Through the solution synthesis of modified phosphoramidites, novel 
nucleotides can be incorporated into an oligonucleotide strand by solid-phase 
synthesis. These modifications can be used in order to alter the properties of 
nucleic acids, thereby expanding their range of applications. 
In this approach,13 the DNA or RNA sequence is grown from a solid 
support, such as controlled-pore glass (CPG), typically in the 3’ to 5’ direction. 
The nucleoside at the 3’-end of the oligonucleotide is synthesized (in solution) 
with a 4,4’-dimethoxytrityl (DMT) protecting group at the 5’-hydroxyl position 
along with protecting groups on the heterocyclic base. The 3’-hydroxyl is then 
converted into the active succinate ester which can be coupled to the amino 
group attached by a long alkyl chain of the functionalized CPG (this step is 
commonly not required as there exists commercially available CPG bound to 
each of the protected 5’-O-DMT nucleosides). A long chain is crucial in order to 
extend the reactive groups away from the surface of the solid-support thereby 
making them accessible for subsequent reactions. Acid treatment removes the 
5’-O-DMT group and exposes a free hydroxyl group. This hydroxyl group then 
couples to an incoming phosphoramidite via an SN2 mechanism (activated by a 
tetrazole catalyst), creating the phosphite linkage. After this step, any unreacted 
5’-hydroxyl groups on the support-bound nucleotide are capped by acetylation to 
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prevent the continued synthesis of undesired sequences. The phosphite triester 
linkage is oxidized by iodine in the presence of water and pyridine. The sequence 
then re-enters the cycle to continue the chain assembly (the cycle is shown in 
Scheme 1.1). Once the full length sequence is complete, it must be cleaved off 
the solid-support and deprotected (Scheme 1.2). Basic conditions are required in 
order to remove the cyanoethyl group from the phosphate backbone via a β-
elimination mechanism (shown in blue in Scheme 1.2). Nucleophilic conditions 
are used to remove the protecting groups on the heterocyclic bases and cleave 
the oligonucleotide from the solid-support (shown in red in Scheme 1.2). 
Commonly, a solution of NH4OH/EtOH (3:1, v/v) is used at elevated temperatures 
in order to achieve deprotection and cleavage in one step. In the case of RNA, a 
subsequent treatment with a fluoride source is required to remove the tert-
butyldimethylsilyl (TBDMS/TBS) group at the 2’-position. When compared to 
Scheme 1.2: A protected support-bound oligonucleotide (left) and a deprotected free 
oligonucleotide (right). 
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naturally occurring sequences, solid-phase synthesized oligonucleotides lack the 
5’ terminal end phosphate group. They may, however, have a 5’ terminal DMT 
which can aid in the purification process. After deprotection and cleavage, 
purification of the desired sequence is required. Common methods include 
denaturing polyacrylamide gel electrophoresis (PAGE) and strong anion 
exchange (SAX) HPLC.  
The efficiency of the phosphoramidite coupling step can be determined 
from the intensity of the absorbance of the cleaved DMT cation at 495 nm. A high 
average stepwise coupling efficiency is required in order to acquire a high yield of 
desired oligonucleotide. The coupling efficiency is never 100 %, thereby instilling 
a length limitation to the solid-phase synthesis methodology. The pore size of the 
solid-support also influences the length of oligonucleotide which can be 
synthesized. CPG with pore sizes of 500 Å are common for the synthesis of 
shorter oligonucleotides, however, for longer sequences, steric influences 
prevent proper diffusion of reagents causing poor coupling reactions. The loading 
of the solid-support, or the moles of nucleoside bound per gram of solid-support, 
is also an important parameter. With high loading supports, steric hindrance 
between adjacent oligonucleotides strands can become an issue as the 
oligonucleotide is elongated.12 
 
1.3. Nucleic Acid X-ray Crystallography  
The technique of X-ray crystallography is used in order to determine high-
resolution structures of biomacromolecules, such as proteins 
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and nucleic acids. A diffraction pattern is generated by irradiating homogenous 
crystals of the desired molecule with X-rays. In order to generate a three-
dimensional electron density map of the molecule, three parameters are 
required, specifically the amplitude, frequency and phase of the diffracted X-
rays.14 From the experimental diffraction pattern, the amplitude and frequency 
can easily be measured. The amplitude is determined from the intensity of the X-
ray reflections and the frequency from the position of the reflections in reciprocal 
space. The phase information, however, is absent and must be determined by 
independent means. This is known as the phase problem in X-ray 
crystallography and constitutes one of the major bottlenecks of the technique. 
Several methods have been developed in order to solve this problem and acquire 
the phase information. The direct method iterates through all possible phase 
angles for each reflection of the diffraction pattern in order to determine the 
phase information by brute-force. This method is not always viable due to 
computational power limitations and currently only works for smaller molecules (< 
1000 non-hydrogen atoms) with atomic resolution diffraction data.15 The 
molecular replacement method relies on the use of a search model, a known 
structure that is homologous to the target molecule. The phase information is 
determined by rotating and translating the search model until it produces a 
simulated diffraction pattern that best matches the observed diffraction pattern. 
Should a homology model not be available, there exist experimental approaches 
to determine phase information, such as multiple isomorphous replacement 
(MIR) and multiple wavelength anomalous diffraction (MAD). In the MIR method, 
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heavy atoms are introduced into the crystal which do not cause any structural 
perturbations, retaining the same crystalline order as the native, unmodified 
crystals. Intensity differences between the X-ray diffraction patterns generated 
from native and heavy atom derivatized crystals allow for the calculation of the 
phases of their associated reflections. It is important to introduce at least two 
different heavy atoms into separate crystals in order to prevent phase ambiguity. 
The MAD method only requires a single heavy atom derivatized crystal which is 
irradiated with X-rays at multiple wavelengths in order to deduce the phase 
information, making it the more attractive and widely used method. In both MIR 
and MAD, techniques to introduce heavy atoms into the crystal include covalent 
modification before crystallization, soaking the native crystal in a solution of 
heavy-atom compounds or growing the crystals in the presence of heavy-atom 
containing molecules (co-crystallization). Commonly, the heavy atoms introduced 
are electron-dense transition metals (third period or lower) capable of 
significantly scattering X-rays, but even atoms such as selenium and bromine 
have successfully been used.14  
With the experimental diffraction data and phase information collected, a 
three-dimensional electron density map of the structure is generated 
computationally. It is then necessary to solve the X-ray crystal structure by model 
building and model refinement. A model is built to best fit the experimental 
electron density map, however inherent errors with the initial phase values must 
be corrected. These corrections are made by model refinement, the process of 
computationally moving atoms of the model in real space, generating a new 
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diffraction pattern in reciprocal space and then determining how well this 
diffraction pattern matches the experimentally determined one. After many 
rounds of model building and refinement, the model converges on the best 
solution.14  
With regard to phasing in nucleic acid X-ray crystallography, the direct 
method may not be ideal for longer oligonucleotides where only low resolution 
diffraction data is available. Molecular replacement is challenging with nucleic 
acids due their highly repetitive units, making the simulated diffraction pattern 
less reliable.15 Furthermore, molecular replacement is not possible for 
determining the phase information of novel structures. The techniques used in 
MIR to introduce heavy atoms into the crystal are frequently problematic for 
nucleic acids. Co-crystallization and soaking with heavy metal cation solutions 
can cause the random cleavage of the phosphate backbone, are prone to non-
specific binding and can cause structural perturbations. Additionally, nucleic acid 
crystals frequently lack large solvent channels for efficient diffusion of heavy 
atoms when the crystal is soaked.16 A classic technique to determine the phase 
problem of nucleic acids by MAD has been bromine derivatization; however this 
strategy also suffers from limitations. Due to the chemical nature of bromine, the 
incorporation sites are fairly limited and have mostly been at the 5-position of 
uracil and cytosine. The carbon-halogen bond is also light sensitive, susceptible 
to radiolysis during X-ray diffraction experiments.15 Furthermore, incorporation of 
bromine commonly causes structural perturbations and even prevents 
crystallization altogether in some instances.16   
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Due to all these limitations, there has been great interest in using 
selenium containing nucleic acids for phasing in X-ray crystallography. Not only 
has the use of selenium found great success in protein X-ray crystallography with 
selenomethionine, it is also ideal for nucleic acids due to the many sites available 
for modification in the scaffold (selenium is a heavier homologue of oxygen). It is 
also much more stable to X-ray irradiation and there are many incorporation sites 
which do not cause significant structural perturbations. Crystallization, the other 
major bottleneck of X-ray crystallography, has also been shown to be facilitated 
with selenium-containing nucleic acids.15     
 
1.4. Selenium Incorporation into Oligonucleotides 
Selenium can be incorporated into nucleic acids by two approaches: 
enzymatic and chemical synthesis. Enzymatic synthesis utilizes DNA and RNA 
polymerases with selenium analogues of deoxyribose nucleoside triphosphates 
(dNTPs) and nucleoside triphosphates (NTPs) as their substrates, respectively.15 
In contrast to solid-phase oligonucleotide synthesis, enzymatic synthesis grows 
the strand in the 5’ to 3’ direction. This method also requires that the 
polymerases actually recognize the selenium analogues as substrates in order to 
catalyze their incorporation. Furthermore, replacement of any one of the four 
dNTP or NTP building blocks with selenium-modified substrates results in 
approximately 25 % nucleotide substitution after the polymerization reaction. In 
contrast to proteins, which only have a 2.2 % natural abundance of methionine,17 
this is quite excessive and may lead to potential problems such as undesirable 
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structural perturbations. The other approach involves the solid-phase synthesis 
of oligonucleotides from phosphoramidite building blocks (described in Chapter 
1.2). This method is advantageous as it provides control of the number of 
selenium atoms incorporated as well as their position in the sequence. Since 
solid-phase synthesis has a length limitation for both DNA and RNA, combined 
strategies have been developed to ligate longer enzymatically synthesized 
sequences to selenium-modified solid-phase synthesized oligonucleotides.18,19 
Through chemical synthesis, selenium has successfully been introduced 
into many sites of nucleic acids. The first instance of selective incorporation of 
selenium into an oligonucleotide by solid-phase synthesis was at the 5’ position 
(Figure 1.4A).20 This was accomplished by the multi-step solution synthesis of 
the 5’-methylseleno phosphoramidite and subsequent solid-phase incorporation 
into an oligonucleotide. This work demonstrated that selenium-containing 
phosphoramidites were compatible with solid-phase synthesis as well as the 
Figure 1.4: Nucleic acid selenium modification sites. 
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stability of selenium-containing oligonucleotides during the deprotection and 
purification steps. Following this work, the first nucleic acid duplex structure was 
solved by MAD phasing using 2’-methylseleno deoxyuridine (Figure 1.4B).21 A 
further example is the preparation of a phosphoramidite with selenium replacing 
the sugar oxygen (Figure 1.4C).22 In a unique approach, during solid-phase 
synthesis certain phosphite backbone positions were converted to the 
corresponding phosphoroselenoate (Figure 1.4D).23 This was achieved by 
replacing the oxidation step in the solid-phase synthesis cycle (involving iodine in 
water / THF / pyridine) with manual treatment of the support-bound 
oligonucleotide with a saturated solution of KSeCN. Each of these incorporation 
sites have been useful in their own right, however they all possess certain 
limitations. Modifications at the 5’-position are limited to the 5’ terminal end of the 
oligonucleotide. Substitutions of the sugar ring (4’-) oxygen are known to be 
synthetically challenging and modifications at the 2’-position may cause 
undesirable structural changes, such as promoting an A-form C3’-endo sugar 
pucker. Finally, replacing the non-bridging phosphate oxygen with selenium 
introduces a new chiral center in the molecule, which necessitates the separation 
of diastereomers by HPLC. This selenium modification was also best tolerated 
near the 5’-end of the oligonucleotide due to deselenization observed after 
multiple cycles of oxidation. More recently, selenium has been introduced at 
different nucleobase sites24,25 through the multi-step synthesis of 
phosphoramidite derivatives, which essentially eliminate the limitations discussed 
above (Figure 1.4E and 1.4F). The X-ray structure of a DNA duplex containing 
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4-selenothymidine (d4SeT) demonstrated that the larger selenium atom is well 
accommodated as the structure was virtually identical to the native duplex. The 
duplex stability and d4SeT/dA base pair were also essentially the same as in the 
unmodified duplex. In a duplex containing 2’-deoxy-6-selenoguanosine (d6SeG), 
the d6SeG/dC base pair was shifted by approximately 0.3 Å, causing a decrease 
in duplex stability; however the overall structure was still very similar to the native 
duplex. Neither one of these cases showed any evidence of deviation from 
normal hydrogen bonding patterns when selenium was present.   
 
1.5. Project Objectives 
To date, X-ray crystallography of biomacromolecules is still a long and 
arduous process and there is great interest in making the technique less time 
consuming. To this end, the present work has gone towards simplifying selenium 
incorporation into oligonucleotides. The previous methods have almost 
exclusively relied on the multi-step synthesis of modified phosphoramidites, 
followed by solid-phase synthesis. This strategy has been quite successful, but 
there remains the possibility for improvement.  
  The Lakshman group26 have described the synthesis of O6-(benzotriazol-
1-yl) inosine and 2’-deoxyinosine derivatives, a class of easily convertible 
nucleoside analogues. A variety of commercially available sugar-protected and -
unprotected inosine and 2’-deoxyinosine nucleosides were treated with 
benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate 
(BOP) in order to introduce the benzotriazolyl group at the 6-position of 
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hypoxanthine. This modification was shown to tolerate different substitutions of 
the sugar oxygen atoms and the benzotriazolyl group could be displaced by a 
variety of nucleophiles. More importantly, these nucleosides could be elaborated 
to the corresponding phosphoramidite and incorporated into an oligonucleotide 
through solid-phase synthesis while retaining the benzotriazolyl group. 
Furthermore, post-synthetic modification was demonstrated as a proof-of-
concept. This was accomplished by the treatment of a benzotriazolyl-containing 
solid-support bound oligonucleotide with nucleophilic morpholine (Scheme 1.3).  
 The Miller group27 also demonstrated the feasibility of post-synthetic 
modifications (Scheme 1.4). A CPG-bound oligonucleotide containing O4-
triazolyl-2’-deoxyuridine was first prepared. The triazole group was displaced by 
the aminoethyl of 5’-O-DMT-3’-O-TBDMS-N4-(2-aminoethyl)deoxycytidine, 
generating a cross-link. The DMT group could then be removed and the 
oligonucleotide further extended by solid-phase synthesis. 
Scheme 1.3: Incorporation of morpholine into a support-bound oligonucleotide 
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Scheme 1.4: Incorporation of an interstrand cross-link into a support-bound 
oligonucleotide. 
 Independently, the Huang group28 developed an effective nucleophilic 
selenium species for incorporation of selenium at the nucleobase. Selenium 
powder is reduced with sodium borohydride in the presence of 3-
bromopropionitrile to generate di(2-cyanoethyl) diselenide. Further reduction of 
the diselenide with sodium borohydride produces nucleophilic 2-cyanoethyl 
selenide. This nucleophile was successfully employed in the synthesis of 
oligonucleotides containing d4SeT and d6SeG nucleotides. The synthetic route for 
d4SeT oligonucleotides is shown in Scheme 1.5 (off-column selenium 
incorporation). This selenium nucleophile is especially useful in that the 
cyanoethyl functionality can be removed in the same step as phosphate 
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backbone deprotection, although special care needs to be taken during this step. 
Deselenization of nucleoside analogs bearing the 2-cyanothyl-seleno 
functionality is possible when treated with strong base. This makes it necessary 
to use phosphoramidites which can be deprotected under ultra-mild conditions, 
such as 50 mM K2CO3 in methanol, during solid-phase synthesis.    
 Based on these previous findings, it should be feasible to treat a support-
bound oligonucleotide containing a convertible nucleoside (with either a triazolyl 
or benzotriazolyl group) with 2-cyanoethyl selenide in order to achieve selenium 
incorporation (on-column approach). This would open up a greener and more 
efficient synthetic route to generating selenium modified oligonucleotides for 
Scheme 1.5: Huang approach for the synthesis of oligonucleotides containing d
4Se
T. 
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X-ray crystallography. This strategy would also have the added advantage of 
producing stock oligonucleotide which could be reused for other purposes due its 
convertible nature. Beyond selenium incorporation, post-synthetic fluorophore 
probes and cross-links could be introduced, to name a few possibilities.  
Inosine is ideal for this approach, as its nucleobase can be readily 
accommodated across either C, A, U/T, and G, thereby reducing the sequence 
identity requirement of nucleic acid structures. This implies that in a nucleic acid 
sequence, any position can be modified with minimal structural perturbation. As a 
proof-of-concept of this approach, it is however preferable to work with DNA. 
Compared to RNA, DNA is less susceptible to chemical degradation, less likely 
to be enzymatically degraded, less expensive and easier to synthesize, both in 
solution and solid-phase. Furthermore, due to previous issues faced in our lab 
with the post-synthetic (on-column) selenium incorporation using 2’-
deoxyinosine, the methodology was first optimized using thymidine. This was 
practical since the synthesis and properties of d4SeT oligonucleotides are well 
established,24,29 allowing for a straightforward  evaluation of the methodology.  
Chapter 2 (unpublished work) explores this topic by describing the 
conditions found to incorporate selenium at the C-4 position of thymidine on a 
support-bound oligonucleotide and retain the selenium functionality after 
deprotection.  
In our efforts to adapt the on-column Se incorporation approach to 2’-
deoxyinosine, it was first necessary to synthesize an authentic oligonucleotide 
containing 2’-deoxy-6-selenoinosine. Unexpectedly, a diselenide bridge was 
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discovered to spontaneously form between two non-complementary strands after 
deprotection and cleavage from the solid-support. The formation and reversibility 
of this cross-link, along with biophysical studies of the cross-linked 
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Chapter 2.  
Selenium Incorporation into a Solid Support-Bound 
Oligonucleotide with Convertible 4-triazolylthymidine 
 
Abstract 
We have explored a simplified methodology for the incorporation of selenium into 
oligonucleotides for use in X-ray crystallography. This strategy involves treating a 
CPG-bound oligonucleotide containing a 5’-terminal 4-triazolylthymidine with a 
nucleophilic selenolate species. This approach has the advantage of generating 
a CPG-bound oligonucleotide which can be recycled for other purposes, beyond 
X-ray crystallography. Conditions were also developed to retain the selenium 
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2.1. Introduction  
Covalent modification of oligonucleotides with selenium (Se) has become 
the gold standard method for solving the phase problem in nucleic acid X-ray 
crystallography. Since Se is a heavier homologue of oxygen, almost all the 
oxygen sites in nucleic acids have synthetically been replaced with Se with 
relative ease. Classically, Se has been incorporated through the multi-step 
synthesis of a phosphoramidite building block bearing a Se functionality in the 
sugar or the nucleobase, followed by solid-phase synthesis of the 
oligonucleotide.20–22,24,25 In one unique case, the non-bridging phosphate oxygen 
was replaced with Se to yield a phosphoroselenoate (P-Se), prepared by 
modification of the conventional solid-phase oxidation step by treatment of the 
support-bound oligonucleotide with the Se reagent KSeCN.30 Although this 
methodology suffered from some limitations, including the necessity for the 
HPLC separation of P-Se diastereomers (effective only for short sequences) and 
deselenization, it was the first successful instance of on-column Se incorporation.  
The Lakshman26 and Miller27 groups demonstrated the feasibility for on-
column incorporations at the nucleobase, utilizing convertible nucleotides, 2’-
deoxy-6-benzotriazolylinosine and 2’-deoxy-4-triazolyluridine, respectively. In 
their approaches, treatment of control-pore glass (CPG) bound oligonucleotides 
with a nucleophilic species caused displacement of the convertible group and 
efficient on-column incorporation. Furthermore, the Huang group28 developed a 
method to generate the nucleophilic 2-cyanoethyl selenide species (from the 
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reduction of di-(2-cyanoethyl) diselenide), which has successfully been 
implemented in the synthesis of Se nucleobase modified phosphoramidites and 
oligonucleotides.24,25  
Inspired by this previous work and the recent push towards greener 
chemistry, we sought out to simplify the Se incorporation process. Herein, we 
describe the development of an on-column nucleobase Se incorporation 
approach utilizing convertible 4-triazolylthymidine. Conditions such as reagent 
concentration, temperature, reaction time and solvent were screened. Using an 
authentically synthesized Se oligonucleotide standard (off-column synthesis), we 
have also determined optimal deprotection conditions for retaining Se in near 
quantitative amounts. 
 By incorporating Se at the nucleobase, no new chiral centers are 
produced and the protected Se functionality, SeEtCN, has been shown to be 
resistant to deselenization during solid-phase synthesis,24 thus avoiding previous 
issues faced with phosphoroselenoates. Furthermore, the convertible CPG-
bound oligonucleotide generated by this process can be recycled for other 
purposes, depending on the nucleophile used for incorporation.  
2.2. Experimental 
2.2.1. General Methods for the Preparation and Characterization of 
Nucleosides 
N,N’-Diisopropylamino cyanoethyl phosphonamidic chloride (Cl-
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POCENiPr2) and 5’-O-(4,4’-dimethoxytrityl)thymidine (compound 2.1) were 
purchased from ChemGenes Corporation (Wilmington, MA). 5’-O-Dimethoxytrityl-
2’-deoxyribonucleoside-3’-O-(β-cyanoethyl-N,N’-diisopropyl) phosphoramidites 
(including 2.8) and protected 2’-deoxyribonucleoside-CPG supports were 
purchased from Glen Research (Sterling, VA). Compounds 2.2, 2.3, 2.4, 2.5 and 
2.6 were synthesized following previously published procedures.24,28 All other 
chemicals and solvents were purchased from the Aldrich Chemical Company 
(Milwaukee, WI) or EMD Chemicals Inc. (Gibbstown, NJ). Flash column 
chromatography was performed using silica gel 60 (230–400 mesh) purchased 
from Canadian Life Science (Pointe-Claire, QC). Thin layer chromatography 
(TLC) was carried out with precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 
mm) purchased from EMD Chemicals Inc. (Gibbstown, NJ). NMR spectra were 
recorded on a Varian 500 MHz NMR spectrometer at room temperature. 1H NMR 
spectra were recorded at a frequency of 500.0 MHz and chemical shifts were 
reported in parts per million (ppm) downfield from tetramethylsilane. 31P NMR 
spectra (1H decoupled) were recorded at a frequency of 202.3 MHz and chemical 
shifts were reported in ppm with H3PO4 used as an external standard. High 
resolution mass spectrometry of modified nucleosides were obtained using an 
7T-LTQ FT ICR mass spectrometer (Thermo Scientific) at the Concordia 
University Centre for Structural and Functional Genomics. The mass 
spectrometer was operated in full scan, positive ion detection mode.  
2.2.2. Chemical Synthesis of Nucleosides  
  27 
3’-O-(2-cyanoethyl-N,N’-diisopropyl)phosphoramidityl-4-(β-2-cyanoethyl)seleno-
5’-O-(4,4’-dimethoxytrityl)-thymidine (2.7) 
To a stirred solution of compound 2.6 (0.264 g, 0.400 mmol) in anhydrous 
THF (2 ml) was added dropwise DIPEA (0.209 ml, 1.20 mmol) followed by the 
dropwise addition of Cl-POCENiPr2 (0.177 ml, 0.799 mmol). After 30 minutes the 
solvent was evaporated in vacuo. The content was diluted with EtOAc (50 ml) 
and washed with 3 % (aq., w/v) NaHCO3 (2 x 50 ml) and brine (50 ml). The 
organic layer was dried over anhydrous Na2SO4, decanted and the solvent 
evaporated in vacuo. Crude material was purified by short flash column 
chromatography using EtOAc/hexanes (4:1, v/v) (with 0.1 % NEt3, v/v) to afford 
0.295 g (86 %) of compound 2.7 as a colorless foam. 31P NMR (202.3 MHz, d6-




To a stirred solution of compound 2.8 (0.516 g, 0.693 mmol) in anhydrous 
DCM/ACN (1:1, v/v) (10 ml) was added 1,2,4-triazole (2.79 g, 40.42 mmol) 
followed by dropwise TEA (6.09 ml, 43.63 mmol). The reaction was cooled to 0oC 
on ice, then dropwise POCl3 (0.813 ml, 8.73 mmol) was added. After 1 hour the 
reaction flask was removed from the ice bath and allowed to stir at room 
temperature for 1 additional hour. The solvent was evaporated in vacuo. The 
content was diluted with DCM (100 ml) and washed with 3 % (aq., w/v) NaHCO3 
(3 x 100 ml). The organic layer was dried over anhydrous Na2SO4, decanted and 
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the solvent evaporated in vacuo. Crude material was purified by short flash 
column chromatography using EtOAc/hexanes (4:1, v/v) (with 0.1 % NEt3, v/v) to 
afford 0.452 g (82 %) of compound 2.9 as a colorless foam. 31P NMR (202.3 
MHz, d6-acetone, ppm): 148.48, 148.23. 
2.2.3. Oligonucleotide Solid-phase Synthesis 
All oligonucleotide sequences were assembled with an Applied 
Biosystems Model 3400 synthesizer on a 2 μmol scale using standard β-
cyanoethyl phosphoramidite cycles supplied by the manufacturer with slight 
modifications to coupling times as described below. The Se containing mixed-
base oligonucleotide (ODN2) was prepared using commercially available 3’-O-2’-
deoxynucleoside phosphoramidites, containing "fast-deprotecting" groups (N6-
phenoxyacetyl-2'-deoxyadenosine, N4-acetyl-2'-deoxycytidine and N2-
phenoxyacetyl-2'-deoxyguanosine), were dissolved in anhydrous ACN to a 
concentration of 0.1 M. The modified 3’-O-2’-deoxynucleoside phosphoramidites 
(compounds 2.7 and 2.9) were dissolved to a concentration of 0.15 M. All other 
oligonucleotides were prepared using a commercially available 3’-O-thymidine 
phosphoramidite, which was dissolved in anhydrous ACN to a concentration of 
0.1 M. Oligonucleotide sequence assembly was carried out as previously 
described.31,32 The capping step for the assembly of ODN2 was carried out using 
phenoxyacetic anhydride/pyridine/THF 1:1:8 (v/v/v; solution A) and 1-methyl-
imidazole/THF 16:84 (w/v; solution B). All other oligonucleotides used acetic 
anhydride/pyridine/THF 1:1:8 (v/v/v, solution A) and 1-methyl-imidazole/THF 
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16:84 (w/v; solution B). The coupling time for phosphoramidites 2.7 and 2.9 were 
extended to 600 seconds (compared to 120 seconds for the commercially 
available phosphoramidites). All oligonucleotides had their 5’-terminal trityl 
groups removed on the synthesizer by acid treatment. 
2.2.4. Deprotection Optimizations of Selenium Containing 
Oligonucleotides  
The solid-phase column was removed from the synthesizer and the CPG-
bound oligonucleotide was transferred to a 2 ml Teflon lined screw cap vial. The 
various conditions and reagents screened for the optimization of the deprotection 
and cleavage of the Se containing oligonucleotides from the solid-support are 
summarized in Table 2.1. After the incubation period, the supernatant was 
transferred to a separate, clean screw cap vial and the CPG washed twice with 
200 μl of aqueous ACN (50 %, v/v). The crude oligonucleotides were lyophilized 
in a speed-vac concentrator.  
2.2.5. Purification of Selenium Containing Oligonucleotides by 
Denaturing PAGE 
The gel consisted of 20 % acrylamide (19:1, w/w, acrylamide to bis-
acrylamide) and 7 M urea in a pH 8.0 TBE buffer (89 mM Tris base, 89 mM boric 
acid, 0.2 mM ethylenediaminetetraacetic acid (EDTA)) with dimensions 20 cm x 
20 cm x 0.75 cm (L x H x W). The gels were run for 2 hours at a constant 10 W 
using the TBE buffer described above. Markers for the gel were a mixture of 
  30 
bromophenol blue (8 nucleotides) and xylene cyanol FF (28 nucleotides). 
Oligonucleotides were prepared by lyophilizing up to 25 OD260 of sample and 
dissolving them in 100 μl formamide. The gel was visualized by placing it on a 
TLC plate (Merck, Kieselgel 60 F254, 0.25 mm) which was irradiated with 254 nm 
light (UV shadowing). The band of interest was then excised from the gel, 
suspended in 0.1 M sodium acetate and shaken gently overnight. The purified 
oligonucleotides were desalted using C-18 SEP PAK cartridges (Waters).  
2.2.6. Quantification of Selenium Containing Oligonucleotides  
After the deprotection trials, each oligonucleotide was purified as stated 
previously and then analyzed by reverse phase (RP) HPLC. The Symmetry® C-
18 5 μm column (0.46 x 15 cm) was eluted with a linear gradient of 0-70 % buffer 
B over 30 min (buffer A: 50 mM sodium phosphate, pH 5.8, 2 % ACN and buffer 
B: 50 mM sodium phosphate, pH 5.8, 50 % ACN). The column was monitored at 
260 nm and 369 nm. The Se containing oligonucleotide was identified by its 
characteristic absorbance at 369 nm and the yield estimated from the area under 
the corresponding peak at 260 nm. 
After the on-column Se incorporation trials, the crude oligonucleotide was 
analyzed by SAX HPLC. The Dionex DNAPAC PA-100 column (0.4 cm x 25 cm), 
purchased from Dionex Corp (Sunnyvale, CA), was eluted at room temperature 
using a linear gradient of 0-52 % buffer B over 30 minutes (buffer A: 100 mM Tris 
HCl, pH 7.5, 10 % ACN; buffer B: 100 mM Tris HCl, pH 7.5, 10 % ACN, 1 M 
NaCl). The column was monitored at 260 nm and 369 nm. The Se containing 
  31 
oligonucleotide was identified by its characteristic absorbance at 369 nm and the 
yield estimated from the area under the corresponding peak at 260 nm. 
2.2.7. Oligonucleotide Characterization by ESI-MS 
ESI mass spectra for oligonucleotides were acquired at the Concordia 
University Centre for Biological Applications of Mass Spectrometry (CBAMS) 
using a Micromass Qtof2 mass spectrometer (Waters) equipped with a 
nanospray ion source. The mass spectrometer was operated in full scan, 
negative ion detection mode and the raw data were deconvoluted. 
2.2.8. On-Column Selenium Incorporation Trials 
Method A: The Se nucleophile was first generated in a round bottom 
flask. The solution was transferred to a syringe which was attached to the solid-
phase column containing the CPG-bound oligonucleotide. The solution was 
pushed through the column over the specified time.  
Method B: The Se nucleophile was first generated in a round bottom 
flask. The solution was transferred to a flame-dried glass vial containing the 
CPG-bound oligonucleotide and sealed.  
Method C: Before the Se nucleophile treatment, neat triethylamine (TEA) 
was washed through the solid-phase column containing the CPG-bound 
oligonucleotide over 2 hours. The column was washed twice with ACN (2x 10 
ml). Next, the column was placed under vacuum to dry for 1 hour.  
Method D: The generation of the Se nucleophile was done in a glass vial 
already containing the CPG-bound oligonucleotide.  
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Method E: The Se nucleophile was first generated in a round bottom 
flask. 1 ml of the solution was added to a syringe and washed through the solid-
phase column containing the CPG-bound oligonucleotide over 20 minutes. 
Another 1 ml of the Se nucleophile was then washed through the column over 20 
minutes. This was repeated for a total of 2 hours. 
Method F: The Se nucleophile was first generated in a round bottom flask. 
The solution was transferred to a screw-cap vial containing the CPG-bound 
oligonucleotide and sealed. 
When 4 Å molecular sieves (MS) are specified, these were placed in the 
round bottom flask during the Se nucleophile synthesis as well as the vessel 
containing the CPG-bound oligonucleotide.  
After each Se nucleophile treatment 
method, the CPG was transferred to a clean solid-
phase column on vacuum (see apparatus in Figure 
2.1). ACN (2x 10 ml) was washed through the 
column (shown in the red box in Figure 2.1). Next, 
the column containing the washed CPG was 
placed under vacuum to dry. The CPG was then 
transferred to a screw cap vial and deprotected 
with t-butylamine/H2O (1:3, v/v) at 60 
oC for 6 
hours, followed by equimolar acetic acid treatment. 
After the incubation period, the supernatant was 
transferred to a separate, clean screw cap vial and the CPG washed twice with 
Figure 2.1: Setup for collecting 
and washing CPG-bound 
oligonucleotides. 
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200 μl aqueous ACN (50 %, v/v). The crude oligonucleotides were lyophilized in 
a speed-vac concentrator. 
2.3. Results and Discussion 
To ensure the deprotection condition used caused minimal deselenization 
Reagents and conditions: (a) TBS-Cl, DMAP, Imidazole, DCM, overnight, rt; (b) 1,2,4-
triazole, TEA, POCl3, DCM/ACN (1:1, v/v), 4 h, 0 
o
C to rt; (c) TREAT-HF, THF, overnight, 
40 
o
C; (d) NaBH4, EtOH, 1 h, 0 
o
C to rt; (e) Cl-POCENiPr2, DIPEA, THF, 30 mins, rt; (f) 
Solid-phase synthesis (see experimental section); (g) 1,2,4-triazole, TEA, POCl3, 
DCM/ACN (1:1, v/v), 3 h, 0 
o
C to rt; (h) On-column Se incorporation; (i) Deprotection. 
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or undesirable adduct formation, the d4SeEtCNT phosphoramidite 2.7 was 
synthesized following the Huang protocol29 and incorporated into an 
oligonucleotide sequence by solid-phase synthesis (off-column approach in 
Scheme 2.1). First, the 3’-position of commercially available 5’-O-dimethoxytrityl-
thymidine 2.1 was protected with a TBS group, generating the protected 
nucleoside 2.2, with a yield of 94 %. Convertible nucleoside 2.3 was synthesized 
by adding a triazolyl group to the C-4 position of protected nucleoside 2.2. The 
TBS group of unpurified convertible nucleoside 2.3 was removed, producing the 
convertible nucleoside 2.4, with a yield of 96 %. Reduction of diselenide28 2.5 by 
sodium borohydride, generating nucleophilic selenolate, allowed for the 
displacement of the triazolyl group to produce pre-amidite 2.6, with a yield of 71 
%. Phosphitylation of pre-amidite 2.6 afforded phosphoramidite 2.7, with a yield 
of 86 %. Phosphoramidite 2.7 was incorporated into the support-bound, 
protected oligonucleotide sequence, 5’-dT4(d
4SeEtCNT)dT5-3’ (ODN1), by solid-
phase synthesis (all trityl values above 90 %). This sequence was chosen in 
order to use the simplest model sequence possible during the deprotection trials, 
as thymidine nucleotides generally do not require nucleobase protection, unlike 
the other canonical nucleotides.  
The results of the deprotection trials of sequence ODN1 (optimization of 
step (i) in Scheme 2.1) are summarized in Table 2.1. The commonly used 
treatment of NH4OH/EtOH (3:1, v/v) was found to be too harsh, causing complete 
deselenization and conversion of the modified nucleobase to 5-methyl-cytosine. 
Treatment with 50 mM K2CO3/MeOH, did retain the Se atom in low yield, but 
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caused methoxy adduct formation. In an attempt to prevent this adduct formation, 
the bulkier alcohol, iPrOH, was chosen to generate the nucleophile for 
deprotection with K2CO3. There were, however, solubility issues with the K2CO3 
and no cleavage of the oligonucleotide from the solid-support was observed. 
Neutralization of the base after the incubation period with an equimolar amount 
of acetic acid resulted in a higher yield of Se containing oligonucleotide, however 
adduct formation was still observed. Finally, treatment with t-butylamine/H2O 
(1:3, v/v) followed by acetic acid neutralization completely abolished adduct 
formation and caused minimal deselenization (Figures A2.7 and A2.8). The 
utility of this deprotection condition was then evaluated for the mixed-base 
oligonucleotide sequence, 5’-dCGCGAA(d4SeEtCNT)dTCGCG-3’ (ODN2). The 
same outcome was observed, as the Se containing oligonucleotide was the 
major species present (Figures A2.9 and A2.10), validating the use of this 
deprotection condition for mixed-base sequences.  
Table 2.1: Deprotection trials of ODN1 in order to retain Se 







  Reagents t (h) T (
o
C)   
1 
ODN1 
NH4OH/EtOH (3:1) 4 55 - 0 
2 50 mM K2CO3/MeOH 4 23 (rt) - 12 
3 50 mM K2CO3/iPrOH 4 23 (rt) - 0 





5 t-butylamine/H2O (1:3) 6 60 - 60 





* Relative yield estimated by RP HPLC 
With the deprotection step optimized for optimal retention of the Se atom, 
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on-column Se incorporation trials were performed (optimization of step (h) in 
Scheme 2.1). First, it was necessary to synthesize the convertible thymidine 
phosphoramidite. Inspired by previous work,33 phosphoramidite 2.9 was 
synthesized in one step, with a yield of 82 %. Phosphoramidite 2.9 was first 
introduced into the sequence 5’-dT4(d
4TriT)dT5-3’ (ODN3), which upon successful 
Se incorporation would generate the same Se oligonucleotide sequence as 
deprotected ODN1. Various methods and conditions for Se incorporation into 
support-bound ODN3 were performed. In each trial, it was necessary to reduce 
diselenide 2.5 to the reactive nucleophilic selenolate species. This was typically 
achieved by following the Huang protocol,28 using sodium borohydride in ethanol. 
 





































 1 rt 0.15 0.30 0 
3
A 
2 rt 0.15 0.30 0 
4
A 
18.5 rt 0.15 0.30 0 
5
CE
 2 rt 0.15 0.30 0 
6
B
 1 rt 0.15 0.30 Yes No No 0 
7
B
 1 rt 0.15 0.30 Yes No Yes 0 
8
B
 1 40 0.15 0.30 Yes No Yes 0 
9
B
 1 60 0.15 0.30 Yes No No 0 
10
B
 4 60 0.15 0.30 Yes No No 0 
11
BC
 1 60 0.15 0.30 Yes No No 0 
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12
B
 0.5 60 0.15 0.90 Yes No No 0 
13
B
 26 60 0.15 0.90 Yes No No 0 
14
BC
 26 60 0.15 0.90 Yes No No 0 
15
BD
 1 rt 0.10 0.20 Yes Yes Yes 0 
16
F



















22 -20 0.20 0.40 No No No 29 
20
F
 48 -20 0.20 0.40 No No No 0 
21
F
 48 rt 0.20 0.40 No No No 0 
22
F
 48 40 0.20 0.40 No No No 0 
23
B
 4 -20 0.20 0.40 No Yes No 0 
24
B
 22 -20 0.20 0.40 No Yes No 0 
25
F
 22 -20 0.20 0.40 No Yes No trace 
26
F
 1 -20 0.20 0.40 No No No 0 
27
F







22 -20 0.20 0.40 No No No 20 
29
F
 4 -20 0.20 0.40 No No No 7.5 
* Relative yield estimated by SAX HPLC 
** N/A: Not applicable  
A: CPG in solid-phase column treated with Se nucleophile solution 
B: CPG in dried glass reaction vial treated with Se nucleophile solution 
C: Prior to the Se nucleophile reaction, treated CPG by washing TEA through the solid-phase 
column over 2 hours 
D: Se nucleophile generated in situ in glass reaction vial containing CPG 
E: Washed Se nucleophile solution through solid-phase column containing CPG, adding more 
equivalencies every 20 minutes 
F: CPG in screw cap vial treated with Se nucleophile solution 
 
 
In some trials (entries 5, 11, 14 and 18), CPG-bound ODN3 was first treated with 
TEA before treatment with the Se nucleophile. This was done in order to remove 
the cyanoethyl groups from the phosphate backbone, generating a negatively 
charged backbone which would be more resistant to cleavage from the Se 
nucleophile. The Se containing oligonucleotide species was identified by its 
characteristic absorbance at 369 nm (Figure A2.11), providing a rapid means to 
identify these oligonucleotides. None of the trials with ODN3 proved fruitful, 
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although from the mass spectrometry analysis of the crude oligonucleotide after 
deprotection, identification of the side-products allowed for more focused 
optimizations going forward. Competing nucleophiles, specifically H2O, hydride 
and t-butylamine were believed to be responsible for these side-products (Figure 
A2.12). The t-butylamine adduct was interesting as it was never observed during 
the deprotection optimizations, however it was believed to form due to the 
presence of unreacted triazole after treatment with the Se nucleophile. 
Furthermore, oxidation of the Se nucleophile produces water as a side-product. 
Using degassed THF as the solvent in order to lower the O2 content was 
attempted, although this did not help, potentially due to solubility issues.  
 After failed attempts with ODN3, phosphoramidite 2.9 was incorporated at 
the 5’-terminal end of a shorter sequence, 5’-(d4TriT)dT4-3’ (ODN4). It was 
suspected that with the reactive triazolyl group at an internal position of an 
oligonucleotide, as in ODN3, steric hindrance may have been preventing proper 
Se incorporation. After Se nucleophile treatment of CPG-bound ODN4 in a screw 
Figure 2.2: SAX HPLC profiles of crude ODN4 after on-column Se nucleophile treatment 
and deprotection (entry 19). 
260 nm 
369 nm 
The column was eluted at room temperature using a linear gradient of 0-52 % 
buffer B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 
100 mM Tris HCl, pH 7.5, 10 % ACN, 1 M NaCl). 
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cap vial at -20 oC and deprotection (entry 19), successful on-column Se 
incorporation was achieved and verified by SAX HPLC (Figure 2.2). From the 
mass spectrometry analysis, the species formed by hydride attack was now 
absent (Figure A2.13). These colder conditions were repeated with ODN3 as well 
as another 10-mer, 5’-(d4TriT)dT9-3’ (ODN5), in order to confirm if it was the 
position of the convertible nucleotide or the length of the oligonucleotide which 
was the main factor preventing on-column Se incorporation. Following treatment 
with the Se nucleophile, no Se containing oligonucleotide was detected when 
using ODN3, however there was a 20 % yield when using ODN5. This suggests 
the position of the convertible nucleotide is vital for proper on-column 
incorporation under these conditions. Finally, lowering the reaction time to 4 
hours at -20 oC significantly lowered the yield of Se oligonucleotide.  
2.4. Conclusion 
In summary, modified oligonucleotides bearing d4SeT nucleotides were 
isolated by two convergent approaches. Deprotection of an authentically 
synthesized Se oligonucleotide with t-butylamine/H2O (1:3) at 60 
oC for 6 hours, 
followed by the addition of equimolar acetic acid, proved to be the optimal 
conditions for retention of Se in homothymidine and mixed-base sequences. The 
on-column Se incorporation approach, although resulting in a lower yield of Se 
oligonucleotide, was shown to be viable in this study for sequences with d4TriT 
and the 5’-terminal end. The position of the convertible group in the 
oligonucleotide sequence was found to be more important than the length of the 
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oligonucleotide, however, a lower yield of Se oligonucleotide was found when 
exposing the longer sequence, ODN5, with the same conditions as ODN4, 
suggesting length does still play a role in efficient incorporation. Further 
optimizations for on-column Se incorporation should be explored in order to 
increase the yield of Se oligonucleotide and make this a viable approach. 
Potentially, by working in a glove box under an inert atmosphere, oxidation of the 
Se nucleophile would be limited, resulting in a more efficient reaction with the 
convertible nucleotide residue. In addition, reaction with water as a competing 
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Abstract 
We have synthesized and characterized a phosphoramidite derivative of 2’-
deoxy-6-selenoinosine (d6SeI) and incorporated this modification into an 
oligonucleotide by solid-phase synthesis. During cleavage from the solid-support 
and deprotection, spontaneous dimerization of this oligonucleotide occurs via 
formation of a diselenide cross-link between the modified nucleobases. This 
cross-link can be readily reduced to restore the single-stranded oligonucleotide. 
UV thermal denaturation and circular dichroism spectroscopy of duplexes with 
d6SeI paired against all four native nucleobases revealed minor differences in 
stability and structure relative to 2’-deoxyinosine. This selenium containing 
nucleobase modification may be useful for applications in DNA nanomaterials 
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3.1. Introduction 
Selenium (Se) derivatized nucleic acids, prepared by either enzymatic or 
solid-phase synthesis, are a powerful tool in solving the phase problem of X-ray 
crystallography due to the anomalous scattering properties of this element.15 The 
substitution of oxygen (O) with Se for this purpose within the nucleic acid scaffold 
has been reported at the phosphate backbone,23 the 2’, 4’ and 5’ positions of the 
sugar21,22,20 and at the nucleobases.24,25 Incorporation of Se at the nucleobase 
has advantages over other sites, including minimal structural perturbation, 
avoiding the introduction of an additional chiral center which would necessitate 
the separation of diastereomers and that incorporation is not limited at the termini 
of the oligonucleotide. Substitution of the O-6 atom of guanine25 and the O4-atom 
of thymine24 with Se are examples 
of nucleoside  modifications that 
have been prepared and 
incorporated into oligonucleotides. 
The crystal structures of Se-
nucleobase modified 
oligonucleotides have been shown 
to be virtually identical to that of 
their native counterparts.15 In 
addition, a nucleic acid-protein 
complex consisting of RNase H/Se-DNA/RNA, has been solved utilizing 
Figure 3.1: Structures of (A) 2'-deoxyinosine, 
(B) 2'-deoxy-6-selenoinosine, and (C) diselenide 
bridged 2'-deoxy-6-selenoinosine. 
  44 
nucleobase Se incorporations.34 
2’-Deoxyinosine (Figure 3.1A), containing the base hypoxanthine, is 
capable of pairing with the other natural nucleobases found in DNA.35  Analogs of 
2’-deoxyinosine have been used to introduce site-specific post-synthetic 
modifications within an oligonucleotide36 and for applications as fluorescent 
probes.37 
Herein, the preparation of a 2’-deoxy-6-selenoinosine (d6SeI, Figure 3.1B) 
phosphoramidite is described. This was achieved by using a convertible 2’-
deoxyinosine nucleoside26 and the Huang reagent (di(2-cyanoethyl) 
diselenide).28 The Se containing phosphoramidite was incorporated into an 
oligonucleotide by solid-phase synthesis, deprotected and purified by strong 
anion exchange (SAX) HPLC to prepare the sequence 5’-
dGGCT6SeIGATCACCAG-3’ (dI-Se-ODN). Interestingly, during the deprotection 
of the oligonucleotide from the controlled pore glass (CPG) solid-support, the 
serendipitous discovery of a cross-linked oligonucleotide homodimer (dI-Se-
ODN2) connected by a diselenide bridge (Figure 3.1C) between the modified 
nucleobases was made. This is the first instance of a Se derivatized nucleic acid 
where two oligonucleotides are cross-linked between the nucleobases with a 
diselenide linkage. dI-Se-ODN2 was studied by UV thermal denaturation, 
denaturing polyacrylamide gel electrophoresis (PAGE) and circular dichroism 
(CD) spectroscopy. Time trials of oligonucleotide dimer formation after 
deprotection were monitored by SAX HPLC. 
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3.2. Experimental 
3.2.1. General Methods for the Preparation and Characterization of 
Nucleosides 
N,N’-Diisopropylamino cyanoethyl phosphonamidic chloride (Cl-
POCENiPr2) and 5’-O-dimethoxytrityl-2’-deoxyinosine (compound 3.1) were 
purchased from ChemGenes Corporation (Wilmington, MA). 5’-O-Dimethoxytrityl-
2’-deoxyribonucleoside-3’-O-(β-cyanoethyl-N,N’-diisopropyl) phosphoramidites 
and protected 2’-deoxyribonucleoside-CPG supports were purchased from Glen 
Research (Sterling, VA). Compounds 3.2 and 3.3 were synthesized following 
previously published procedures.26,28 All other chemicals and solvents were 
purchased from the Aldrich Chemical Company (Milwaukee, WI) or EMD 
Chemicals Inc. (Gibbstown, NJ). Flash column chromatography was performed 
using silica gel 60 (230–400 mesh) purchased from Canadian Life Science 
(Pointe-Claire, QC). Thin layer chromatography (TLC) was carried out with 
precoated TLC plates (Merck, Kieselgel 60 F254, 0.25 mm) purchased from EMD 
Chemicals Inc. (Gibbstown, NJ). NMR spectra were recorded on a Varian 500 
MHz NMR spectrometer at room temperature. 1H NMR spectra were recorded at 
a frequency of 500.0 MHz and chemical shifts were reported in parts per million 
(ppm) downfield from tetramethylsilane. 13C NMR spectra (1H decoupled) were 
recorded at a frequency of 125.7 MHz and chemical shifts were reported in ppm 
with tetramethylsilane as a reference. 77Se NMR spectra (1H decoupled) were 
recorded at a frequency of 95.3 MHz and chemical shifts were reported in ppm 
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with dimethyl selenide used as an external standard. 31P NMR spectra (1H 
decoupled) were recorded at a frequency of 202.3 MHz and chemical shifts were 
reported in ppm with H3PO4 used as an external standard. High resolution mass 
spectrometry of modified nucleosides were obtained using an 7T-LTQ FT ICR 
mass spectrometer (Thermo Scientific) at the Concordia University Centre for 
Structural and Functional Genomics. The mass spectrometer was operated in full 
scan, positive ion detection mode. 
3.2.2. Chemical Synthesis of Nucleosides  
6-(2-cyanoethyl)seleno-5’-O-(4,4’-dimethoxytrityl)-2’-deoxyinosine (3.4) 
In separate round bottom flasks, diselenide 3.3 (0.475 g, 1.79 mmol) was 
dissolved in 99 % EtOH (10 ml), NaBH4 (0.169 g, 4.45 mmol) was suspended in 
99 % EtOH (2.5 ml) and compound 3.2 (0.294 g, 0.438 mmol) was dissolved in 
anhydrous THF (2.5 ml). The atmosphere in all three flasks was exchanged with 
argon. The flask containing diselenide 3.3 (yellow solution) was stirred and 
immersed in an ice bath to cool for 10 minutes. The NaBH4 suspension was 
injected dropwise over 5 minutes. After the cessation of gas evolution, the flask 
was removed from the ice bath (solution now clear). The solution of compound 
3.2 was then injected dropwise. After 2 hours the reaction mixture was diluted 
with EtOAc (100 ml) and washed with brine (2 x 100 ml). The organic layer was 
dried over anhydrous Na2SO4, decanted and the solvent evaporated in vacuo. 
Crude material was purified by flash column chromatography using a gradient of 
MeOH/DCM (0 % to 3 % increased by increments of 0.5 %, v/v) to afford 0.192 g 
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(66 %) of compound 3.4 as a colorless foam. Rf (SiO2 TLC): 0.64 (9:1 
EtOAc/hexanes, v/v). λmax (ACN): 286 nm. 
1H NMR (500 MHz, CDCl3, ppm): δ 8.63 
(s, 1H, H8), 8.16 (s, 1H, H2), 7.40-7.38 (m, 2H, Ar), 7.29-7.19 (m, 7H, Ar), 6.79 
(m, 4H, Ar), 6.47 (dd, 1H, H1’ J = 6.5 Hz), 4.70 (m, 1H, H3’), 4.17 (m, 1H, H4’), 
3.78 (s, 6H, 2x OCH3), 3.55 (t, 2H, CH2-Se, J = 7.4 Hz), 3.44-3.37 (m, 2H, H5’’, 
H5’), 3.02 (t, 2H, CH2-CN, J = 7.3 Hz), 2.86 (m, 1H, H2’), 2.56 (m, 1H, H2’’), 2.49 
(s, 1H, OH). 13C NMR (125.7 MHz, CDCl3, ppm): 158.58, 157.27, 151.92, 147.72, 
144.43, 141.95, 135.59, 135.56, 134.57, 129.98, 128.04, 127.90, 126.97, 118.85, 
113.20, 86.64, 86.25, 84.64, 72.48, 63.66, 55.24, 40.20, 19.34, 18.49. 77Se NMR 
(95.3 MHz, CDCl3, ppm): 323.60. IR (thin film); νmax (cm
-1) 3354, 2932, 2251, 
1608, 1566, 1508, 1333, 1251, 1178, 1033. HRMS (ESI-MS) m/z calculated for 
C34H33N5O5NaSe




To a stirred solution of compound 3.4 (0.139 g, 0.207 mmol) in anhydrous 
THF (2 ml) was added dropwise DIPEA (0.108 ml, 0.620 mmol) followed by the 
dropwise addition of Cl-POCENiPr2 (0.092 ml, 0.416 mmol). After 30 minutes the 
solvent was evaporated in vacuo. The content was diluted with EtOAc (50 ml) 
and washed with 3 % (aq., w/v) NaHCO3 (2 x 50 ml) and brine (50 ml). The 
organic layer was dried over anhydrous Na2SO4, decanted and the solvent 
evaporated in vacuo. Crude material was purified by short flash column 
chromatography using EtOAc/hexanes (4:1, v/v) (with 0.1 % NEt3, v/v) to afford 
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0.158 g (88 %) of compound 3.5 as a colorless foam. Rf (SiO2 TLC): 0.89, 0.84 
(4:1 EtOAc/hexanes, v/v). λmax (ACN): 286 nm. 
1H NMR (500 MHz, d6-acetone, 
ppm): δ 8.64 (s, 0.5H, H8), 8.63 (s, 0.5H, H8), 8.49 (s, 0.5H, H2), 8.48 (s, 0.5H, 
H2), 7.46-7.43 (m, 2H, Ar), 7.34-7.18 (m, 7H, Ar), 6.85-6.79 (m, 4H, Ar), 6.60-
6.56 (m, 1H, H1’), 5.03-4.94 (m, 1H, H3’), 4.37-4.30 (m, 1H, H4’), 3.97- 3.63 (m, 
12H, CH2OP, 2x NCH, 2x OCH3, CH2-Se), 3.48-3.39 (m, 2H, H5’, H5’’),  3.29-
3.22 (m, 1H, H2’), 3.16-3.13 (m, 2H, OCH2CH2CN), 2.79-2.66 (m, 3H, 
SeCH2CH2CN, H2’’), 1.24-1.14 (m, 12H, 4 x CH3). 
13C NMR (125.7 MHz, d6-
acetone, ppm): 158.69, 158.67, 157.02, 151.57, 147.89, 147.87, 145.14, 143.59, 
143.58, 135.87, 135.85, 135.80, 134.76, 134.74, 130.08, 130.05, 130.04, 130.00, 
128.09, 128.04, 127.63, 127.62, 126.64, 126.62, 118.98, 118.09, 117.96, 112.95, 
112.93, 86.14, 85.80, 85.76, 85.64, 85.59, 84.94, 84.93, 74.00, 73.87, 73.41, 
73.28, 63.72, 63.54, 58.87, 58.77, 58.72, 58.62, 54.66, 54.64, 43.15, 43.12, 
43.05, 43.02, 38.23, 38.20, 38.18, 38.14, 24.08, 24.06, 24.04, 24.02, 24.00, 
23.98, 19.95, 19.89, 19.84, 18.70, 18.40. 31P NMR (202.3 MHz, d6-acetone, 
ppm): 148.31, 148.20. 77Se NMR (95.3 MHz, d6-acetone, ppm): 334.39. IR (thin 
film); νmax (cm
-1) 2965, 2927, 2365, 2338, 2251, 1608, 1560, 1508, 1333, 1250, 
1179, 1077, 1034. HRMS (ESI-MS) m/z calculated for C43H51N7O6PSe
+: 
872.2798; found 872.2795 [M + H]+. 
3.2.3. Oligonucleotide Solid-phase Synthesis 
All oligonucleotide sequences were assembled with an Applied 
Biosystems Model 3400 synthesizer on a 2 μmol scale using standard β-
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cyanoethyl phosphoramidite cycles supplied by the manufacturer with slight 
modifications to coupling times as described below. Se containing 
oligonucleotides were prepared using commercially available 3’-O-2’-
deoxynucleoside phosphoramidites, containing "fast-deprotecting" groups (N6-
phenoxyacetyl-2'-deoxyadenosine, N4-acetyl-2'-deoxycytidine and N2-
phenoxyacetyl-2'-deoxyguanosine), which were dissolved in anhydrous ACN to a 
concentration of 0.1 M. The modified 3’-O-2’-deoxynucleoside phosphoramidite 
(compound 3.5) used in the preparation of these oligonucleotides was dissolved 
to a concentration of 0.15 M. All other oligonucleotides were prepared using 
commercially available 3’-O-2’-deoxynucleoside phosphoramidites, containing 
standard protecting groups (N6-benzoyl-2'-deoxyadenosine, N4-benzoyl-2'-
deoxycytidine and N2-isobutyryl-2'-deoxyguanosine), which were dissolved in 
anhydrous ACN to a concentration of 0.1 M. Oligonucleotide sequence assembly 
was carried out as previously described.31,32 The capping step of the assembly 
was carried out using phenoxyacetic anhydride/pyridine/THF 1:1:8 (v/v/v; solution 
A) and 1-methyl-imidazole/THF 16:84 (w/v; solution B). The coupling time for 
phosphoramidite 3.5 was extended to 600 seconds (compared to 120 seconds 
for the commercially available phosphoramidites). All oligonucleotides had their 
5’-terminal trityl groups removed on the synthesizer by acid treatment. 
3.2.4. Oligonucleotide Deprotection and Purification  
The solid-phase column was removed from the synthesizer and the CPG-
bound oligonucleotide was transferred to a 2 ml Teflon lined screw cap vial. The 
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Se containing oligonucleotide was deprotected and cleaved from the solid 
support by treatment with 1 ml of freshly prepared t-butylamine/H2O (1:3, v/v) 
containing 50 mM dithiothreitol (DTT) for 6 hours at 60 oC, followed by the 
addition of an equimolar amount of glacial acetic acid. All other oligonucleotides 
were deprotected and cleaved from the solid support with a treatment of 1 ml 
NH4OH/EtOH (3:1) for 4 hours at 55 
oC. After the incubation periods, the 
supernatant was transferred to a separate, clean screw cap vial and the CPG 
washed twice with 200 μl aqueous ACN (50 %, v/v). The crude oligonucleotides 
were lyophilized in a speed-vac concentrator.  
All oligonucleotides were purified by strong anion exchange (SAX) HPLC 
using a Dionex DNAPAC PA-100 column (0.4 cm x 25 cm) purchased from 
Dionex Corp (Sunnyvale, CA). The column was eluted at room temperature using 
a linear gradient of 0-52 % buffer B over 30 minutes (buffer A: 100 mM Tris HCl, 
pH 7.5, 10 % ACN; buffer B: 100 mM Tris HCl, pH 7.5, 10 % ACN, 1 M NaCl). 
The column was monitored at 260 nm and 352 nm for analytical runs and 260 nm 
and 280 nm for preparative runs. The purified oligonucleotides were desalted 
using C-18 SEP PAK cartridges (Waters). The purified dI-Se-ODN sample was 
stored in an aqueous (18 MΩ) solution of 50 mM DTT. The purified dI-Se-ODN2 
sample was stored in 18 MΩ H2O. 
3.2.5. Oligonucleotide Characterization by ESI-MS 
ESI mass spectra for oligonucleotides were acquired at the Concordia 
University Centre for Biological Applications of Mass Spectrometry (CBAMS) 
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using a Micromass Qtof2 mass spectrometer (Waters) equipped with a 
nanospray ion source. The mass spectrometer was operated in full scan, 
negative ion detection mode and the raw data were deconvoluted. 
3.2.6. Time Trials of Oligonucleotide Dimer Formation after 
Deprotection 
The CPG-bound oligonucleotide was transferred to a 2 ml Teflon lined 
screw cap vial. The CPG was treated with 1 ml of freshly prepared t-
butylamine/H2O (1:3, v/v) at 60
oC. At different time points, a 20 μl aliquot was 
diluted to 500 μl using 18 MΩ H2O with the addition of an equimolar amount of 
glacial acetic acid. After 18 hours, a sample was prepared with the extra addition 
of 50 μl of 0.5 M DTT which was allowed to incubate for 2 hours at room 
temperature before analysis. Each sample was vortexed, centrifuged and 
injected into the SAX HPLC. The column was eluted as described above. 
3.2.7. Denaturing Polyacrylamide Gel Electrophoresis (PAGE) of 
Oligonucleotides 
The gel consisted of 20 % acrylamide (19:1, w/w, acrylamide to bis-
acrylamide) and 7 M urea in a pH 8.0 TBE buffer (89 mM Tris base, 89 mM boric 
acid, 0.2 mM ethylenediaminetetraacetic acid (EDTA)) with dimensions 10 cm x 
7.5 cm x 0.75 mm (L x H x W). The gel was run for 1.5 hours at 200 V using the 
TBE buffer described above. Markers for the gel were a mixture of bromophenol 
blue (8 nucleotides) and xylene cyanol FF (28 nucleotides). Oligonucleotides 
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were prepared by lyophilizing 0.1 OD260 of sample and dissolving in 10 μl 
formamide. Prior to loading on the gel, dI-Se-ODN2 samples were treated with 10 
mM DTT, 10 mM glutathione (GSH) or 10 mM NaBH4 for 2 hours at room 
temperature, lyophilized in a speed-vac concentrator and dissolved in 10 μl 
formamide. The gel was visualized by placing it on a TLC plate (Merck, Kieselgel 
60 F254, 0.25 mm) which was irradiated with 254 nm light (UV shadowing).  
3.2.8. UV Thermal Denaturation Studies of DNA Duplexes 
Molar extinction coefficients for the unmodified and Se modified 
oligonucleotides were calculated from those of the mononucleotides using 
nearest-neighbor approximations (M-1 cm-1). The molar extinction coefficient of 
2’-deoxyinosine was used for the Se modified nucleotide. Oligonucleotide dI-Se-
ODN2 (1 equiv.) was mixed with the complement strands (2 equiv.). All other 
duplexes were prepared by mixing equimolar amounts of the interacting strands. 
The mixtures were then lyophilized to dryness in a speed-vac concentrator. The 
resulting pellet was dissolved in 1 ml buffer (pH 7.0) containing 90 mM NaCl, 10 
mM sodium phosphate and 1 mM EDTA. Samples containing dI-Se-ODN and dI-
ODN had an additional 2.5 mM DTT in solution with a final duplex concentration 
of 3.7 μM. Samples of dI-Se-ODN2 did not contain DTT and had a final 
oligonucleotide dimer concentration of 1.0 μM. Samples were heated at 95 oC for 
10 minutes then allowed to slowly come down to room temperature for 1 hour 
and placed in the fridge overnight. Prior to the thermal run, samples were 
degassed by placing them in a speed-vac concentrator for 2 minutes. Thermal 
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melting (Tm) curves were acquired at 260 nm starting at 15 
oC and increasing the 
temperature at a rate of 0.5 oC/min until 95 oC, using a Varian CARY Model 3E 
spectrophotometer fitted with a 6-sample thermostated cell block and a 
temperature controller. Denaturing data processing was carried out as described 
by Puglisi and Tinoco38 and transferred to Microsoft ExcelTM software. 
3.2.9. Circular Dichroism (CD) Spectroscopy of DNA Duplexes  
Circular dichroism spectra were obtained on a Jasco J-815 
spectropolarimeter equipped with a Julaba F25 circulating bath. Samples were 
allowed to equilibrate for 5 minutes at 15 oC in 90 mM NaCl, 10 mM sodium 
phosphate, 1 mM EDTA (pH 7.0). Samples of dI-Se-ODN and dI-ODN had an 
additional 2.5 mM DTT in solution with a final duplex concentration of 3.7 μM. 
Samples of dI-Se-ODN2 did not contain DTT and had a final oligonucleotide 
dimer concentration of 1.0 μM.  Each spectrum was an average of 5 scans, 
collected at a rate of 20 nm/min, with a bandwidth of 1 nm and sampling 
wavelength of 0.2 nm using fused quartz cells (Starna 29-Q-10). The spectra 
were recorded from 320 to 220 nm at 15 oC. The molar ellipticity [θ] was 
calculated from the equation [θ] = ε/Cl, where ε is the relative ellipticity (mdeg), C 
is the molar concentration of DNA duplex (M), and l is the path length of the cell 
(cm). The data were processed using software supplied by the manufacturer 
(JASCO, Inc.) and transferred to Microsoft ExcelTM software. 
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3.3. Results and Discussion 
Electrophilic O6-(benzotriazol-1-yl)-2’-deoxyinosine26 3.2, first described by 
Lakshman, was synthesized from commercially available 5’-O-dimethoxytrityl-2’-
deoxyinosine 3.1, with a yield of 74 % (Scheme 3.1). Reduction of diselenide28 
3.3, generating nucleophilic selenolate, allowed for the displacement of the 
benzotriazolyl group to produce 3.4, with a yield of 66 %. Phosphitylation of 3.4 
afforded phosphoramidite 3.5, with a yield of 88 %. The phosphoramidite was 
Reagents and conditions: (a) PyBOP, DBU, DMF, 4 h, rt; (b) NaBH4, EtOH, 2 h, 0 
o
C to 
rt; (c) Cl-POCENiPr2, DIPEA, THF, 30 mins, rt. 
Scheme 3.1: Synthesis of the d
6Se
I phosphoramidite (3.5). 
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introduced into the CPG-bound DNA sequence 5’-dGGCT6SeIGATCACCAG-3’ by 
solid-phase synthesis (Scheme 3.2). All trityl values after phosphoramidite 
coupling were above 90 % indicating successful incorporation of the modified 
phosphoramidite.  
Conventional deprotection with NH4OH/EtOH (3:1, v/v) was found to be 
too harsh to accomplish  removal of the protective groups while retaining Se in 
the oligonucleotide, necessitating the use of a milder t-butylamine/H2O (1:3, v/v) 
treatment followed by the addition of an equimolar amount of glacial acetic acid 
to neutralize the amine base (Scheme 3.2). Unexpectedly, rather than the 
desired oligonucleotide dI-Se-ODN, the dimerized dI-Se-ODN2 was the major 
product after deprotection and liberation from the solid-support. The formation of 
this dimer was first suspected during the SAX HPLC purification of the crude 
oligonucleotide. Elution times for sequences 14 nucleotides in length are 
expected to be in the range of 18-22 minutes under the buffer conditions 
Scheme 3.2: Synthesis of the dI-Se-ODN and formation of dI-Se-ODN2. 
Reagents and conditions: (a) Solid-phase synthesis (see experimental section); (b) (i) 
t-butylamine/H2O (1:3, v/v) in 50 mM  DTT, 6 h, 60
o
C; (ii) glacial acetic acid; (c) (i) t-
butylamine/H2O (1:3, v/v), 6 h, 60 
o
C (ii) glacial acetic acid. 
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employed by SAX HPLC (specified in Figure 3.2); however, the major species 
generated had an elution time closer to 26 minutes (Figure 3.2a). Furthermore, 
4-selenothymidine and 2’-deoxy-6-selenoguanosine containing oligonucleotides 
have characteristic UV absorptions at 369 nm and 360 nm, respectively.25,29 
Absorption at 352 nm was observed for the d6SeI containing oligonucleotides 
(Figure A3.10); however, the major species generated had minimal absorbance 
at this wavelength (Figure 3.2a), especially when compared to the minor 
species. In order to account for such a drastic decrease in absorbance intensity 
at 352 nm, it was hypothesized that a modification occurred at or near the Se 
position of the oligonucleotide. The major species was collected, desalted, and 
analysed by ESI-MS, which confirmed a higher than expected molecular mass. 
The mass observed corresponded to a diselenide bridged oligonucleotide 
homodimer (Figure A3.12). Unfortunately, attempts to digest dI-Se-ODN2 by 
Figure 3.2: SAX HPLC traces of (a) crude dI-Se-ODN2 monitored at (i) 260 nm and (ii) 
352 nm (b) crude dI-Se-ODN monitored at (i) 260 nm and (ii) 352 nm (c) pure dI-Se-
ODN2 monitored at (i) 260 nm and (ii) 352 nm (d) pure dI-Se-ODN monitored at (i) 260 
nm and (ii) 352 nm 
The column was eluted at room temperature using a linear gradient of 0-52 % buffer 
B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 100 mM 
Tris HCl, pH 7.5, 10 % ACN, 1 M NaCl). 
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methods previously used in our group were not successful.39 This may be due to 
the nuclease not being able to digest the oligonucleotide at the cross-linked site 
or that buffer used for digestion compromises the Se-Se cross-link.   
In order to isolate dI-Se-ODN and confirm the presence of a diselenide 
bond, deprotection of the CPG-bound oligonucleotide was repeated, but with the 
addition of the reducing agent dithiothreitol (DTT). The major species in the SAX 
HPLC profile now had a reduced elution time of approximately 22 minutes and an 
intense absorbance at 352 nm (Figure 3.2b), which were characteristic of the 
d6SeI containing 14-mer. No peak at 26 minutes was observed. After collecting 
and desalting the major species, SAX HPLC indicated the dimer had reformed 
(Figure 3.2c). Re-addition of DTT to the solution allowed for the isolation of pure 
dI-Se-ODN (Figure 3.2d), which was confirmed by ESI-MS (Figure A3.14). 
Storage of dI-Se-ODN at 4 oC in the absence of DTT was shown to prevent 
dimerization, even after 1 week (data not shown). 
To test if the deprotection condition used contributed to dimerization, 
deprotection was repeated with another mild treatment: 0.05 M K2CO3/MeOH for 
4 h at room temperature, with and without the addition of an equimolar amount of 
glacial acetic acid. In both instances, the major species was once again dI-Se-
ODN2 (data not shown). Furthermore, removal of DTT during desalting of crude 
dI-Se-ODN initiated re-dimerization. These results suggest spontaneous (without 
the addition of an oxidizing agent) diselenide bridge formation is occurring. 
Interestingly, 2’-deoxy-6-selenoguanosine containing oligonucleotides have not 
been reported to readily self-dimerize.25 Potentially, the C-2 exocyclic amino 
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group of guanine sterically prevents diselenide bond formation between the 6-
seleno atoms. Thio-nucleobase-modified oligonucleotides have been shown to 
form disulfide bridges in complementary sequences where the bridging atoms 
are in proximity to one another after hybridization.40,41 
In order to observe the timescale of dimerization after cleavage from the 
solid-support, time trials were performed by analysing the crude dI-Se-ODN 
oligonucleotide by SAX HPLC after deprotection in the absence of DTT. 
Dimerization was however, too fast under these experimental conditions. After 
only 2 hours of deprotection, dI-Se-ODN2 was already the predominant species, 
with no evidence of dI-Se-ODN accumulating over time (Figure A3.17). This 
suggests that at elevated temperatures (60 oC), diselenide bridge formation is 
rapid and occurs soon after cleavage from the solid-support and removal of the 
cyanoethyl group protecting the 6-seleno atom. After 18 hours of deprotection, 
incubation of the crude oligonucleotide with 50 mM DTT for 2 hours quantitatively 
reverted the dimer (dI-Se-ODN2) to the single-stranded species (dI-Se-ODN) 
(Figure A3.17).  
UV thermal denaturation of duplexes between dI-Se-ODN with 
complementary strands where d6SeI is base paired with dA, dC, dG and dT 
nucleotides were performed. The buffers for these experiments contained 2.5 
mM DTT in order to avoid the self-dimerization of the d6SeI containing 
oligonucleotide.  The denaturation profiles revealed Tm values which were 
comparable to duplexes containing unmodified 2’-deoxyinosine (Figure A3.18). 
This suggests there is no significant destabilization of the duplex upon Se 
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modification at the 6-position of 2’-deoxyinosine. Furthermore, the CD spectra of 
the same dI-Se-ODN containing duplexes showed typical B-form DNA 
signatures, with a wavelength maximum at 280 nm, an intercept near 260 nm 
and a minimum around 250 nm, similar to the control 2’-deoxyinosine containing 
duplexes (Figure A3.19). This suggests the Se modification has minimal 
influence on the global DNA structure.  
UV thermal denaturation experiments of dI-Se-ODN2 in the presence of 2 
equivalents of the complementary strands produced Tm curves which were 
biphasic in nature and the CD spectra also showed typical B-form DNA 
signatures (Figures A3.20 and A3.21). The biphasic Tm curves may be due to 
the dissociation of the first, then second equivalent, of the complementary strand 
hybridized to dI-Se-ODN2. Denaturing PAGE was used in order to evaluate the 
efficiency of other reducing agents on diselenide bridge removal of dI-Se-ODN2, 
specifically NaBH4 and glutathione (GSH) (Figure A3.22). Both of these reagents 
caused the loss of the dimer band after only 2 hours of incubation at room 
temperature, with migrations similar to dI-Se-ODN. A significant smearing in the 
GSH lane was observed, perhaps due to incomplete removal of the GSH in 
loading of the oligonucleotide onto the gel. In the untreated dI-Se-ODN2 lane, two 
bands were observed. Electrolytic reduction of the diselenide bond is believed to 
occur, producing the lower band which migrates with the dI-Se-ODN control in 
lane 4; a significant amount of dimer remained. Electrolytic reduction of insulin 
disulfide bonds has previously been reported.42 
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3.4. Conclusion  
In summary, the synthesis and characterization of a novel Se modified 2’-
deoxyinosine phosphoramidite has been described. In the absence of reducing 
agents such as DTT, the crude oligonucleotide forms a homodimer linked by a 
diselenide bridge. This dimer can readily be reduced to restore the single 
stranded oligonucleotide upon treatment with agents such as DTT, NaBH4 and 
GSH. Duplexes containing d6SeI paired with any of the four natural nucleobases 
of DNA revealed minimal perturbation to duplex thermal stability and structure 
relative to 2’-deoxyinosine.  
Future work will involve crystallizing and solving the X-ray crystal structure 
of duplexes containing this novel Se containing 2’-deoxyinosine derivative.  
Formation and crystallization of a diselenide cross-linked DNA duplex and 
structural determination by X-ray crystallography may be advantageous in 
solving the structures of larger nucleic acid assemblies given that the Se phasing 
power is proportional to the number of Se atoms incorporated (one Se atom per 
30 nucleotides).43 
Beyond X-ray crystallography, these diselenide cross-linked 
oligonucleotides may find applications as stimuli responsive materials given their 
reactivity relative to species containing disulfide bonds.44,45,46 These materials 
may be attractive as a molecular switch able to respond to the intracellular 
reducing environment.47  
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Chapter 4. Conclusions and Future Work 
4.1. General Conclusions 
Using an authentically synthesized d4SeEtCNT containing oligonucleotide, 
the optimal deprotection conditions were determined for retaining Se in near 
quantitative amounts. This was found to be a treatment of t-butylamine/H2O (1:3; 
v/v) for 6 hours at 60 oC, followed by equimolar 100 % acetic acid to neutralize 
the amine. By minimizing deselenization and adduct formation, pure samples of 
Se oligonucleotides can be obtained which should facilitate crystallization. 
Conditions to incorporate Se into solid-support bound oligonucleotides containing 
a convertible 4-triazolyl-thymidine were also determined, however, the best yield 
was only 29 % (estimated by SAX HPLC), necessitating further optimization. The 
on-column Se incorporation was finally achieved by performing the reaction at -
20 oC.  
Through the synthesis of an authentic d6SeI containing oligonucleotide, 
unexpected cross-linking through the formation of a diselenide bond was 
observed between two non-complementary strands. This phenomenon was 
interesting as it was not reported in oligonucleotides containing d6SeG 
nucleotides, suggesting that the C-2 exocyclic amino group of guanine sterically 
prevents dimerization. This spontaneous diselenide bridge forms soon after 
deprotection at 60 oC and can be reversed with treatment of DTT, NaBH4 or 
GSH. Under reducing conditions, it was found that d6SeI containing 
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oligonucleotides possess a characteristic absorbance at 352 nm. This property 
can be exploited in the HPLC purification of these oligonucleotides. Thermal 
denaturation and CD studies showed that the Se modification was well tolerated 
in the duplex, with and without the diselenide cross-link.  
4.2. Future Work  
Further optimization of the on-column Se incorporation conditions is 
required in order to maximize the yield of the desired oligonucleotide product. 
Working under an inert atmosphere in a glove box may prevent undesirable 
oxidation of Se or deselenization due to ambient moisture. Longer reaction times 
should be investigated to ensure complete conversion of the triazolyl functionality 
to prevent undesired adduct formation. Furthermore, using a CPG support with a 
lower nucleoside loading could decrease the steric hindrance between growing 
strands and potentially increase the efficiency of Se incorporation. Once on-
column Se incorporation has been optimized at the 5’-end, it would be ideal to 
explore the introduction of Se at internal positions of the oligonucleotide. 
Additionally, it may be of interest to test the viability of further extension of the 
Scheme 4.1: An alternative approach for on-column Se incorporation. 
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oligonucleotide after on-column Se incorporation at the terminal end. Both of 
these approaches could enable Se incorporation at any position in the sequence. 
Should optimizations of the on-column methodology using a convertible 
nucleoside ultimately afford low yielding results, a new approach, illustrated in 
Scheme 4.1, could be attempted. This approach would involve the synthesis of 
an anhydrothymidine phosphoramidite, as shown in step 1, followed by solid-
phase synthesis of the oligonucleotide in step 2 and finally, in step 3, the on-
column introduction of the Se functionality at the 2’-position, deprotection and 
purification.43 It has previously been shown that anhydro nucleosides are 
compatible with solid-phase synthesis conditions and they are even suitable for 
post-synthetic modifications.48 This approach may have the advantage of being 
less sensitive to moisture resulting in deselenization.  
With regard to the diselenide cross-linked oligonucleotides, it would be 
desirable to harness the dimerization reaction in order to expand to scope of this 
fundamental finding to prepare other well-defined cross-linked species. The 
determination of conditions that prevent self-dimerization and instead promote 
cross-linking to a different, complementary oligonucleotide would broaden the 
range of nucleic acid assemblies that can be constructed. It was shown that 
lower temperatures can prevent spontaneous diselenide bridge formation when 
the strands are non-complementary.49 When incubating two complementary 
oligonucleotides with d6SeI nucleotides opposing one another at 4 oC in an 
aqueous DTT solution, duplex formation without cross-linking occurs. Quickly 
desalting the oligonucleotide solution (to remove DTT) and resuspending in cold 
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water would reinitiate duplex formation, placing the Se atoms in close proximity. 
Over time, diselenide bridge formation could occur. If the temperature was found 
to be too low for the diselenide cross-link to form, it could be increased slowly, 
but never above the duplex Tm value to ensure the major species in solution was 
the duplex. This strategy could be explored to produce diselenide cross-linked 
heterodimeric duplexes. With crystals of the duplex, it would be possible to 
determine its high-resolution structure by X-ray crystallography, utilizing the 2 Se 
atoms for phasing. This would shed light on how the local environment of the 
duplex shifts in order to accommodate the cross-link. 
With a better understanding of the spatial arrangement of the diselenide 
cross-link, it could potentially be utilized to design small circular DNA. One such 
design strategy is shown in Scheme 4.2. The d6SeI monomer could be introduced 
Scheme 4.2: Synthesis of small circular DNA utilizing the diselenide cross-link. 
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into an oligonucleotide sequence by solid-phase synthesis (step 1). The 
sequence illustrated is only one example; sequences of different nucleobase 
composition and length could also be evaluated. After deprotection of the 
oligonucleotide in the presence of reducing dithiothreitol (DTT), the crude 
oligonucleotide would be purified by SAX HPLC. By monitoring the eluent at 352 
nm, the Se containing oligonucleotide can be selectively identified and collected. 
During the desalting process, DTT would be removed, which initiates 
spontaneous oxidation to form the diselenide cross-link between the strands 
(step 2). The strands should then hybridize as illustrated. The free 5’-OH groups 
would be phosphorylated and ligated to give the circular species (steps 3 and 4). 
It is anticipated that the structure of the circular DNA will be different in the 
presence and absence of the cross-link. Structural differences can readily be 
evaluated by denaturing PAGE and CD spectroscopy. It has previously been 
difficult to confirm circularization, but this issue could be addressed by 
engineering 2’-deoxyuridine monomers into the sequence. Treatment with the 
enzyme uracil deglycosylase followed by piperidine should allow for controlled 
cleavage into products that will confirm successful ligation and circularization 
(step 5). This can be accomplished by denaturing PAGE, providing fast 
visualization of the oligonucleotide cleavage products present. Furthermore, 
electrospray ionization mass spectrometry of the cleavage products would be 
possible.  
Diselenide cross-linked circular DNA between non-complementary strands 
could be used to bind a target sequence with higher affinity and selectivity than 
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standard Watson Crick pairing.50 These small circular DNA have been shown to 
be more resistant to degradation in human serum when compared to single 
stranded or duplex DNA.51 A recent study described the utilization of small 
circular oligonucleotides in the formation of DNA nanotubes.52  
Going forward, it may be possible to introduce the diselenide cross-link 
into other, more complex topologies, such as triplexes and tetrameric species, in 
order to stabilize them. Multiple cross-link incorporations may be needed in these 
instances, but this shouldn’t pose a challenge owing to the synthetic ease by 
which the diselenide can be incorporated. This would also be where the dual 
functionality of Se is best displayed: by promoting the formation of novel nucleic 
acid structures and facilitating the determination of their high resolution X-ray 
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Figure A2.9: RP HPLC profiles of ODN2 deprotected with t-butylamine/H2O + AcOH. The column was 
eluted with a linear gradient of 0-70 % buffer B over 30 min (buffer A: 50 mM sodium phosphate, pH 5.8, 
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Figure A2.12: ESI-MS spectrum of crude ODN3 after on-column Se nucleophile treatment and 
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Figure A2.13: ESI-MS spectrum of crude ODN4 after on-column Se nucleophile treatment and 
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Scheme A2.1: Synthesis of diselenide 2.5. Reagents and conditions: (a) (i) NaBH4, 1,4-dioxane/EtOH 
(4:1, v/v), 1 h, rt (ii) 3-bromopropionitrile, 1 h, rt.   
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Figure A3.5: 500 MHz 1H NMR spectrum of compound 3.5 (in d6-acetone) 
d6-acetone 
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Figure A3.6: 125.7 MHz 13C NMR spectrum of compound 3.5 (in d6-acetone) 
 
d6-acetone d6-acetone 
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Figure A3.7: 202.3 MHz 31P NMR spectrum of compound 3.5 (in d6-acetone) 
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Figure A3.8: 95.3 MHz 77Se NMR spectrum of compound 3.5 (in d6-acetone) 
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Figure A3.10: UV-Vis spectra of dI-Se-ODN and dI-ODN. The dI-Se-ODN spectrum is shown in blue, 
the dI-ODN spectrum is shown in red and the blank 18 MΩ H2O spectrum is shown in black. Samples 
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Figure A3.11: SAX HPLC profiles of purified dI-Se-ODN2. (a) 260 nm profile. (b) 352 nm profile. (c) 
Expansion of 352 nm profile. The column was eluted at room temperature using a linear gradient of 0-52 
% buffer B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 100 mM Tris HCl, 
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Figure A3.13: SAX-HPLC profiles of purified dI-Se-ODN. (a) 260 nm profile. (b) 352 nm profile. (c) 
Expansion of 352 nm profile. The column was eluted at room temperature using a linear gradient of 0-52 
% buffer B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 100 mM Tris HCl, 
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Figure A3.15: SAX-HPLC profiles of purified dI-ODN. (a) 260 nm profile. (b) 352 nm profile. (c) 
Expansion of 352 nm profile. The column was eluted at room temperature using a linear gradient of 0-52 
% buffer B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 100 mM Tris HCl, 
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Figure A3.17: SAX HPLC traces of the crude d6SeI containing oligonucleotide at different times after 
deprotection. The deprotection condition used was t-butylamine/H2O (1:3, v/v) at 60
oC followed by the 
addition of an equimolar amount of glacial acetic acid. Red trace: 1 hour after deprotection; blue trace: 2 
hours after deprotection; green trace: 3 hours after deprotection; black trace: 18 hours after deprotection 
followed by the addition of 50 mM DTT. The column was eluted at room temperature using a linear 
gradient of 0-52 % buffer B over 30 minutes (buffer A: 100 mM Tris HCl, pH 7.5, 10 % ACN; buffer B: 
100 mM Tris HCl, pH 7.5, 10 % ACN, 1 M NaCl). 
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Figure A3.18: Tm values of duplexes containing d
6SeI or dI across different base pairing partners. The 
sequence of the DNA duplex was 5´ dGGCTXGATCACCAG 3´ / 5´ dCTGGTGATCYAGCC 3´ where X 
is d6SeI or dI and Y is dC, dA, dG or dT. The solutions contained a final duplex concentration of 3.7 μM in 
a pH 7.0 buffer consisting of 90 mM NaCl, pH 7.0, 10 mM sodium phosphate, 1 mM EDTA and 2.5 mM 
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Figure A3.19: CD spectra of DNA duplexes. (a) 2’-Deoxy-6-selenoinosine nucleotide in duplexes 5’ 
dGGCT6SeIGATCACCAG 3’ / 5’ dCTGGTGATCYAGCC 3’. (b) 2’-Deoxyinosine nucleotide in duplexes 5’ 
dGGCTIGATCACCAG 3’ / 5’ dCTGGTGATCYAGCC 3’. The solutions contained a final duplex 
concentration of 3.7 μM in a pH 7.0 buffer consisting of 90 mM NaCl, 10 mM sodium phosphate, 1 mM 















Figure A3.20: Tm curves of dI-Se-ODN2 with different complements. The solutions 
contained a final oligonucleotide dimer concentration of 1.0 μM in a pH 7.0 buffer 
consisting of 90 mM NaCl, pH 7.0, 10 mM sodium phosphate and 1 mM EDTA. Data 
was acquired at 0.5 °C/min from 15oC to 95oC, monitoring UV absorption at 260 nm. 
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Figure A3.21: CD spectra of dI-Se-ODN2 with different complements. The solutions contained a final 
oligonucleotide dimer concentration of 1.0 μM in a pH 7.0 buffer consisting of 90 mM NaCl, 10 mM 
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Figure A3.22: Denaturing PAGE of dI-Se-ODN2 treated with various reducing agents. Lane 1: dye 
markers (upper band: xylene cyanol FF; lower band: bromophenol blue); lane 2: 28-mer ssDNA (5’ 
d(AT)14 3’); lane 3: dI-Se-ODN2; lane 4: dI-Se-ODN; lane 5: dI-Se-ODN2 treated with 10 mM DTT; lane 
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Scheme A3.1: Synthesis of diselenide 3.3. Reagents and conditions: (a) (i) NaBH4, 1,4-dioxane/EtOH 
(4:1, v/v), 1 h, rt (ii) 3-bromopropionitrile, 1 h, rt.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
